Nutritional vitamin D supplementation in dialysis: A randomized trial

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 4, 2015, Pages 611-619

  Bhan, Ishir ^a   Dobens, Dorothy ^a   Tamez, Hector ^a   Deferio, Joseph ^a   Li, Yan Chun ^d   Warren, H Shaw ^b   Ankers, Elizabeth ^a   Wenger, Julia ^a   Tucker, J Kevin ^a   Trottier, Caitlin ^a   Pathan, Fridosh ^c   Kalim, Sahir ^a   Nigwekar, Sagar U ^a   Thadhani, Ravi ^a  

^a Division of Nephrology   (United States)

^b Infectious Disease Unit   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PLACEBO; VITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL METABOLISM; MINERAL SUPPLEMENTATION; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; KIDNEY DISEASES; MORTALITY; NUTRITIONAL STATUS; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VITAMIN D DEFICIENCY;

ADMINISTRATION, ORAL; ADULT; AGED; BIOMARKERS; CAUSE OF DEATH; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NEW ENGLAND; NUTRITIONAL STATUS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84926619104     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06910714     Document Type: Article

References (43)

1. Holick MF:VitaminDdeficiency. NEnglJMed 357: 266–281, 2007
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, Prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1–S130, 2009
3. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB: Effect of cholecalciferol supplementation during winter months in patients with hypertension: A randomized, placebo-controlled trial. Am J Hypertens 25: 1215–1222, 2012
4. Bhan I, Camargo CA, Wenger J, Ricciardi C, Ye J, Borregaard N, Thadhani R: Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol 127: 1302, 2011
5. Camargo CA, Ganmaa D, Frazier AL, Kirchberg FF, Stuart JJ, Kleinman K, Sumberzul N, Rich-Edwards JW: Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 130: 561–567, 2012
6. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR, Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker R D, Mein CA, Bhaw-Rosun L, Nuamah R, Young DB, Drobniewski FA, Griffiths CJ, Martineau AR: Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109: 15449–15454, 2012
7. Hewison M: VitaminDand immune function: autocrine, paracrine or endocrine? Scand J Clin Lab Invest Suppl 243: 92–102, 2012
8. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK: Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6: 231–243, 2009
9. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A: 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naïve CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167: 4974–4980, 2001
10. Smolders J, Thewissen M, Peelen E, Menheere P, Tervaert JW, Damoiseaux J, Hupperts R: Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 4: e6635, 2009
11. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004–1013, 2007
12. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24: 503–510, 2004
13. Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R: Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 5: 460–467, 2010
14. Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36–43, 2007
15. Kandula P, Dobre M, Schold JD, Schreiber MJ, Mehrotra R, Navaneethan SD: Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6: 50–62, 2011
16. Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18: 375–382, 2008
17. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC, Custodio MR, Pecoits-Filho R: Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Renal Nutr 22: 284–291, 2012
18. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitaminD supplementation. Nephrol Dial Transplant24: 3799–3805, 2009
19. Shah N, Bernardini J, Piraino B: Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25: 362–366, 2005
20. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23: 4016–4020, 2008
21. Nigwekar SU, Bhan I, Thadhani R: Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60: 139–156, 2012
22. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks ofmortality and endstage renal disease in patients with chronic kidney disease. JAMA 305: 2432–2439, 2011
23. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584–592, 2008
24. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: Evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110: c58–c65, 2008
25. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V: Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study. Endocr Pract 14: 10–17, 2008
26. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S: Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis 59: 58–66, 2012
27. Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H: Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 30: 407–410, 2008
28. Oksa A, Spustova V, Krivosıkova Z, Gazdıkova K, Fedelesova V, Lajdova I, Stefıkova K, Bernasovska G, Zilinska Z, Dzurik R: Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 31: 322–329, 2008
29. Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, Nybo M, Rasmussen LM, Hansen D, Scholze A: Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 27: 3523–3531, 2012
30. Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R: 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 7: 1428–1434, 2012
31. Seibert E, Heine GH, Ulrich C, Seiler S, Kohler H, Girndt M: Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: A randomized, double-blind, placebo-controlled clinical trial. Nephron Clin Pract 123: 209–219, 2013
32. Hewitt NA, O’Connor AA, O’Shaughnessy DV, Elder GJ: Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8: 1143–1149, 2013
33. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: c132–c138, 2007
34. Lac PT, Choi K, Liu IA, Meguerditchian S, Rasgon SA, Sim JJ: The effects of changing vitaminD levels on anemia in chronic kidney disease patients: A retrospective cohort review. Clin Nephrol74: 25–32, 2010
35. Albitar S, Bourgeon B, Genin R, Fen-Chong M, N’Guyen P, Serveaux MO, Atchia H, Schohn D: Bilateral retrobulbar optic neuritiswith hepatitis B vaccination. Nephrol Dial Transplant 12: 2169–2170, 1997
36. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS: Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 7: 624–631, 2012
37. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR,Thadhani R: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369: 1991–2000, 2013
38. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I: Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 26: 1609–1616, 2011
39. Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, Thadhani RI: Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 82: 84–89, 2012
40. Schwartz JB, Lai J, Lizaola B, Kane L, Markova S, Weyland P, Terrault NA, Stotland N, Bikle D: A comparison of measured and calculated free 25(OH) vitaminDlevels in clinical populations. J Clin Endocrinol Metab 99: 1631–1637, 2014
41. Schwartz JB, Lai J, Lizaola B, Kane L, Weyland P, Terrault NA, Stotland N, Bikle D: Variability in free 25(OH) vitaminDlevels in clinical populations. J Steroid BiochemMol Biol 144: 156–158, 2014
42. Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89: 5387–5391, 2004
43. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R: Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 68: 854–858, 1998